NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M
NervGen Pharma, a spinal cord injury-focused biotech listed on Nasdaq, filed unaudited interim financials for the period ended September 30, 2026. Cash rose to C$80.1M from C$22.1M at year-end, mainly from a May 2026 public offering and option and warrant exercises. A C$33.9M unrealized gain on the warrant derivative produced nine-month net income of C$2.5M, even though operating expenses rose to C$30.3M and the company posted a Q3 net loss of C$6.4M.
16 Nov 2026 · Nervgen Pharma Corp. NGEN · Company news
Company's press release (SEC filing): Nervgen Pharma Corp. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More FinancingAll →
Financing
Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3
16 Nov 2026 · Kyntra Bio, Inc. KYNB · Company news
Financing
Windward Bio closes $251.2M IPO and private placement, with underwriters' option exercised in full
16 Nov 2026 · Windward Bio Group AG · Company news
Financing
Hydrofarm posts Q3 2026 sales drop to $14.5M and wipes out $109M term loan in October recapitalization
16 Nov 2026 · Hydrofarm Holdings Group, Inc. HYFM · Company news
Financing
AMC Robotics posts Q3 2026 net loss of $2.02M on lower revenue and one-time financing costs
16 Nov 2026 · AMC Robotics Corp AMCI · Company news
Financing
Grande Group signs $40M ordinary share purchase facility with White Lion Capital
16 Nov 2026 · Grande Group Ltd/HK GRAN · Company news
Financing
Akebia secures up to $140M Symbiotic Capital term loan, repays $55M BlackRock facility
16 Nov 2026 · Akebia Therapeutics, Inc. AKBA · Company news